This surrogate of ALK rearrangement may also lead to misclassification of ROS1 fusion (also associated with an increased VTE risk19) positive NSCLC as ALK-positive in a minority of patients (~15% of those classified as ALK-positive patients treated after January 2017, when this indication was approved32). Here, ROS1 is linked to non-small cell lung carcinoma.